

Inex Pharmaceuticals Corporation

[View the current Inex Pharmaceuticals Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/bioporporate/5541-Inex+Pharmaceuticals+Corporation.html)

(<http://www.bioportfolio.com/bioporporate/5541-Inex+Pharmaceuticals+Corporation.html>)

Contact Details:

100 - 8900 Glenlyon Parkway Glenlyon Business

Park

Tel: 604 419 3200

Burnaby

Fax: 604 419 3204

British Columbia

Email:

V5J 5JB

Canada

INEX Pharmaceuticals Corporation is a biopharmaceutical company that utilizes proprietary drug delivery systems and therapeutic compounds to increase the effectiveness and reduce the side-effects of anti-cancer therapies.

INEX's strategy has been to develop technology capable of making anti-cancer drugs more effective and reducing their side-effects, thus giving these drugs a competitive advantage in the marketplace. The basic approach has been to encapsulate the drugs in a lipid envelope that is carried through the bloodstream and delivered to disease sites where the drugs are released to carry out their therapeutic action.

Recent Publications by Inex Pharmaceuticals Corporation:



- [Methods for the preparation of protein-oligonucleotide-lipid constructs.](#)
*A mixture of ionizable cationic lipids, steric barrier lipids, and...*13th July, 2006
Inex Pharmaceuticals Corporation, 100-8900 Glenlyon Parkway, Burnaby, BC,- Bioconjug Chem. 2006 Mar-Apr;17(2):451-8. ([DOI Direct Link](#))
- [Micelles as intermediates in the preparation of protein-liposome conjugates.](#)
*A method for preparing protein-liposome conjugates based on micelles as...*13th July, 2006
Inex Pharmaceuticals Corporation, 100-8900 Glenlyon Parkway, Burnaby, BC,- Bioconjug Chem. 2006 Mar-Apr;17(2):438-50. ([DOI Direct Link](#))
- [Reliability of preparation procedure for sphingosomal vincristine.](#)
*PURPOSE: The reliability of the preparation procedure for sphingosomal...*31st December, 2005
Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.- Am J Health Syst Pharm. 2005 Aug 1;62(15):1606-12. ([DOI Direct Link](#))
- [Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine](#)

[with promising antitumor activity.](#)

Vinorelbine (VRL) is a particularly lipophilic member of the vinca... 13th August, 2005

Inex Pharmaceuticals Corporation, 200-8900 Glenlyon Parkway, Glenlyon- J Pharm Sci. 2005

May;94(5):1024-38. ([DOI Direct Link](#))

- [Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.](#)

Polyethylene glycol (PEG) is used widely in the pharmaceutical industry to... 6th April, 2005

Inex Pharmaceuticals Corporation, 100-8900 Glenlyon Parkway, Burnaby, BC,- J Pharmacol Exp Ther.

2005 Mar;312(3):1020-6. Epub 2004 Nov 3. ([DOI Direct Link](#))

- [Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.](#)

Immunostimulatory oligodeoxynucleotides (ODN) are effective adjuvants in... 26th June, 2004

Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.- J Invest Dermatol. 2004

Apr;122(4):1042-9. ([DOI Direct Link](#))

- [A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma.](#)

To analyze the available literature describing the treatment of relapsed... 26th November, 2002

Inex Pharmaceuticals Corporation, Burnaby, BC, Canada.- Leuk Lymphoma. 2002 May;43(5):975-82.

- [Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.](#)

Topotecan was encapsulated in sphingomyelin/cholesterol liposomes using an... 19th August, 2000

Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada.- Cancer Res. 2000 Jul

1;60(13):3389-93.

Press Releases on Inex Pharmaceuticals Corporation:

["As an Industry,](#)

[We've Been too](#)

[Focused on Regulatory](#)

[Approval," Says Solvay](#)

[Pharmaceuticals Eric](#)

[Rambeaux at the](#)

[Pharma Marketing](#)

[Summit.](#)

26th November,

2009

LONDON, November 26

/PRNewswire/ -- Rambeaux joined a host of other industry leaders at eyeforpharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[Heska Announces](#)

[Supply Agreement With](#)

[Roche Diagnostics](#)

25th November,

2009

Heska Corporation

LOVELAND, Colo., Nov. 25

/PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA); ("Heska"), a leading provider of advanced diagnostic and specialty products to the veterinary industry,

[Onyx Pharmaceuticals](#)

[Announces December](#)

[2009 Investor Events](#)

25th November,

2009

Onyx Pharmaceuticals, Inc.

EMERYVILLE, Calif., Nov. 25

/PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7,

[Remedium](#)

[Technologies Wins Most](#)

[Promising Security Idea](#)

[at Global Security](#)

[Challenge 2009 with](#)

[Blood-Clotting Foam](#)

25th November,
2009

Maryland Technology
Enterprise Institute

COLLEGE PARK, Md., Nov. 25
/PRNewswire-USNewswire/ --
Remedium Technologies Inc., a
company developing a shaving
cream-like foam that stops severe
bleeding, won first prize and
\$10,000 in the Most

[Video: Genworth](#)

[Recognizes the](#)

[Nation's](#)

[Caregivers in New Ad](#)

[Campaign](#)

25th November,
2009

Genworth Financial

RICHMOND, Va., Nov. 25
/PRNewswire-FirstCall/ -- There are
120 million reasons to recognize
caregivers in the U.S., and
Genworth Financial (NYSE: GNW)
will celebrate and give thanks to
these men and

BioNews Results for Inex Pharmaceuticals Corporation



- [NUCRYST Announces Special Meeting of Shareholders](#)
KLFY: Nov 22 2009 12:21AM Matching: pharmaceuticals
- [Alnylam Pharmaceuticals Down 21.5% Since SmarTrend's Sell Recommendation](#)
TradingMarkets: Nov 21 2009 7:26PM Matching: pharmaceuticals
- [NUCRYST Announces Special Meeting of Shareholders](#)
TickerTech.com: Nov 21 2009 8:43PM Matching: pharmaceuticals
- [NUCRYST Announces Special Meeting of Shareholders](#)
KSLA: Nov 21 2009 7:19PM Matching: pharmaceuticals
- [NUCRYST Announces Special Meeting of Shareholders](#)
Montana's News Station: Nov 21 2009 12:32PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)
MedIndia: Nov 20 2009 4:45AM Matching: pharmaceuticals
- [Minster Pharma. PLC : Interim Results](#)
Investigate: Nov 20 2009 7:44AM Matching: pharmaceuticals
- [NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference](#)
Reuters: Nov 20 2009 8:58PM Matching: pharmaceuticals
- [Company Profile for Amneal Pharmaceuticals, LLC](#)
Reuters: Nov 20 2009 4:21PM Matching: pharmaceuticals
- [Endo Pharmaceuticals \(ENDP\) Trading On Heavy Volume - Zibb.com](#)
Zibb: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Endo Pharmaceuticals \(ENDP\) Trading On Heavy Volume - Zibb.com](#)
Zibb: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Endo Pharmaceuticals and LecTec Settle Patent Dispute](#)
Pharma Live: Nov 20 2009 3:36PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)
SmartBrief: Nov 20 2009 6:49AM Matching: pharmaceuticals
- [Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffra...](#)
Zibb: Nov 19 2009 10:22PM Matching: pharmaceuticals
- [Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation](#)



Inex Pharmaceuticals Corporation Clinical Trials:

- [Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma](#)



Inex Pharmaceuticals Corporation Patents:

- 7247316- [Compositions and methods for treating lymphoma](#)
- 6287591- [Charged therapeutic agents encapsulated in lipid particles containing four lipid components](#)
- 6110745- [Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method](#)
- 5981501- [Methods for encapsulating plasmids in lipid bilayers](#)
- 5976567- [Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer](#)
- 5965542- [Use of temperature to control the size of cationic liposome/plasmid DNA complexes](#)
- 5814335- [Sphingosomes for enhanced drug delivery](#)
- 5785992- [Compositions for the introduction of polyanionic materials into cells](#)
- 5753613- [Compositions for the introduction of polyanionic materials into cells](#)
- 5741516- [Sphingosomes for enhanced drug delivery](#)
- 5705385- [Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer](#)
- 5595756- [Liposomal compositions for enhanced retention of bioactive agents](#)
- 5543152- [Sphingosomes for enhanced drug delivery](#)
- 6320017- [Polyamide oligomers](#)
- 6534484- [Methods for encapsulating plasmids in lipid bilayers](#)
- 7244450- [Compositions and methods for treating lymphoma](#)
- 7094423- [Methods for preparation of lipid-encapsulated therapeutic agents](#)
- 7060828- [Liposomal camptothecins and uses thereof](#)
- 6986902- [Polyanionic polymers which enhance fusogenicity](#)
- 6858225- [Lipid-encapsulated polyanionic nucleic acid](#)
- 6858224- [Method of preventing aggregation of a lipid:nucleic acid complex](#)
- 6841538- [Combination therapy using nucleic acids and radio therapy](#)
- 6815432- [Methods for encapsulating plasmids in lipid bilayers](#)
- 6734171- [Methods for encapsulating nucleic acids in lipid bilayers](#)
- 6723338- [Compositions and methods for treating lymphoma](#)
- 6586559- [Polyamide oligomers](#)

- 6586410- [Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer](#)
- 5478860- [Stable microemulsions for hydrophobic compound delivery](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

